KR102755545B1 - 프로모터 - Google Patents
프로모터 Download PDFInfo
- Publication number
- KR102755545B1 KR102755545B1 KR1020187024944A KR20187024944A KR102755545B1 KR 102755545 B1 KR102755545 B1 KR 102755545B1 KR 1020187024944 A KR1020187024944 A KR 1020187024944A KR 20187024944 A KR20187024944 A KR 20187024944A KR 102755545 B1 KR102755545 B1 KR 102755545B1
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- nucleic acid
- polynucleotide
- acid molecule
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 125
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 125
- 239000002157 polynucleotide Substances 0.000 claims abstract description 125
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 81
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 78
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 78
- 210000004027 cell Anatomy 0.000 claims abstract description 67
- 238000013518 transcription Methods 0.000 claims abstract description 43
- 230000035897 transcription Effects 0.000 claims abstract description 43
- 239000013604 expression vector Substances 0.000 claims abstract description 31
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 25
- 230000001737 promoting effect Effects 0.000 claims abstract description 10
- 239000002773 nucleotide Substances 0.000 claims description 58
- 125000003729 nucleotide group Chemical group 0.000 claims description 58
- 239000013598 vector Substances 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 19
- 238000001890 transfection Methods 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 230000003612 virological effect Effects 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 239000013600 plasmid vector Substances 0.000 claims description 7
- 241000713666 Lentivirus Species 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241000701447 unidentified baculovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 18
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 61
- 102000004169 proteins and genes Human genes 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 32
- 239000012634 fragment Substances 0.000 description 23
- 229920002873 Polyethylenimine Polymers 0.000 description 16
- 238000001262 western blot Methods 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 108700009124 Transcription Initiation Site Proteins 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108091023040 Transcription factor Proteins 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 239000013592 cell lysate Substances 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000003146 transient transfection Methods 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091029523 CpG island Proteins 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 108010034634 Repressor Proteins Proteins 0.000 description 3
- 102000009661 Repressor Proteins Human genes 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108091026908 Downstream promoter element Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
- 102000006290 Transcription Factor TFIID Human genes 0.000 description 1
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 1
- 102000004408 Transcription factor TFIIB Human genes 0.000 description 1
- 108090000941 Transcription factor TFIIB Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- -1 hnRNA Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1603577.6 | 2016-03-01 | ||
| GBGB1603577.6A GB201603577D0 (en) | 2016-03-01 | 2016-03-01 | Promoter |
| PCT/GB2017/050537 WO2017149292A1 (en) | 2016-03-01 | 2017-02-28 | Promoter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180132045A KR20180132045A (ko) | 2018-12-11 |
| KR102755545B1 true KR102755545B1 (ko) | 2025-01-17 |
Family
ID=55807149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187024944A Active KR102755545B1 (ko) | 2016-03-01 | 2017-02-28 | 프로모터 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10647999B2 (enExample) |
| EP (2) | EP3423583B1 (enExample) |
| JP (1) | JP6960409B2 (enExample) |
| KR (1) | KR102755545B1 (enExample) |
| CN (1) | CN109072251A (enExample) |
| AU (1) | AU2017225350B2 (enExample) |
| GB (3) | GB201603577D0 (enExample) |
| SG (1) | SG11201806782QA (enExample) |
| WO (1) | WO2017149292A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110892064A (zh) | 2017-07-25 | 2020-03-17 | 牛津遗传学有限公司 | 腺病毒载体 |
| CN107630035A (zh) * | 2017-09-28 | 2018-01-26 | 兰州大学 | 一种大鼠防御素真核表达载体及其构建方法 |
| GB201800903D0 (en) | 2018-01-19 | 2018-03-07 | Oxford Genetics Ltd | Vectors |
| BR112020015798A2 (pt) | 2018-02-01 | 2021-03-09 | Homology Medicines, Inc. | Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas |
| GB201901571D0 (en) | 2019-02-05 | 2019-03-27 | Oxford Genetics Ltd | Inducible AAV sysyem |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007081336A1 (en) | 2006-01-13 | 2007-07-19 | Five Prime Therapeutics, Inc. | Mammalian vectors for high-level expression of recombinant proteins |
| WO2012112603A1 (en) | 2011-02-14 | 2012-08-23 | University Of Utah Research Foundations | Constructs and methods for generating induced pluri potent stem ( ips) cells |
| WO2016022075A1 (en) | 2014-08-08 | 2016-02-11 | Agency For Science, Technology And Research | Mutants of the bacteriophage lambda integrase |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA014757B1 (ru) * | 2006-02-28 | 2011-02-28 | Вэксарт, Инк. | Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью и выделенная нуклеиновая кислота |
| US9388425B2 (en) * | 2006-10-20 | 2016-07-12 | Trustees Of Boston University | Tunable genetic switch for regulating gene expression |
| EP2097538A4 (en) * | 2006-12-07 | 2011-11-30 | Switchgear Genomics | TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS |
| DK2477652T3 (en) * | 2009-09-16 | 2015-07-20 | Vaxart Inc | Immunization strategy for the prevention of infection H1Ni |
| EP2611915B1 (en) * | 2010-09-01 | 2015-04-15 | Cellagenics B.V. | Nucleic acid fragments from a ribosomal protein promoter for enhancing gene expression |
| AU2012238601B2 (en) | 2011-04-07 | 2017-01-12 | Bayer Cropscience Nv | Seed - specific promoter in cotton |
| US9234197B2 (en) * | 2011-10-28 | 2016-01-12 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona For And On Behalf Of Arizona State University | Genetic element that enhances protein translation |
| DK2711426T3 (en) * | 2012-09-24 | 2015-07-13 | Lonza Biologics Plc | Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences |
| DK2971005T3 (da) | 2013-03-12 | 2020-08-24 | Agc Biologics Inc | Forbedret rekombinant proteinekspression ved anvendelse af en hybrid CHEF1-promotor |
| CN104630267B (zh) * | 2014-07-17 | 2017-10-31 | 清华大学 | 利用tale转录抑制子在哺乳动物细胞中模块化构建合成基因线路的试剂盒 |
-
2016
- 2016-03-01 GB GBGB1603577.6A patent/GB201603577D0/en not_active Ceased
-
2017
- 2017-02-28 GB GB2002193.7A patent/GB2578859B/en not_active Expired - Fee Related
- 2017-02-28 AU AU2017225350A patent/AU2017225350B2/en active Active
- 2017-02-28 WO PCT/GB2017/050537 patent/WO2017149292A1/en not_active Ceased
- 2017-02-28 EP EP17712536.6A patent/EP3423583B1/en active Active
- 2017-02-28 CN CN201780014321.9A patent/CN109072251A/zh active Pending
- 2017-02-28 SG SG11201806782QA patent/SG11201806782QA/en unknown
- 2017-02-28 JP JP2018545660A patent/JP6960409B2/ja active Active
- 2017-02-28 KR KR1020187024944A patent/KR102755545B1/ko active Active
- 2017-02-28 US US16/080,765 patent/US10647999B2/en active Active
- 2017-02-28 GB GB1703224.4A patent/GB2553170B/en not_active Expired - Fee Related
- 2017-02-28 EP EP20157991.9A patent/EP3686282B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007081336A1 (en) | 2006-01-13 | 2007-07-19 | Five Prime Therapeutics, Inc. | Mammalian vectors for high-level expression of recombinant proteins |
| WO2012112603A1 (en) | 2011-02-14 | 2012-08-23 | University Of Utah Research Foundations | Constructs and methods for generating induced pluri potent stem ( ips) cells |
| WO2016022075A1 (en) | 2014-08-08 | 2016-02-11 | Agency For Science, Technology And Research | Mutants of the bacteriophage lambda integrase |
Non-Patent Citations (2)
| Title |
|---|
| Gene Med.,11:941-950(2009.) |
| NCBI GenBank: LM652706.1(2015.8.24.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017149292A1 (en) | 2017-09-08 |
| AU2017225350A1 (en) | 2018-09-06 |
| JP6960409B2 (ja) | 2021-11-05 |
| KR20180132045A (ko) | 2018-12-11 |
| GB2553170B (en) | 2020-05-06 |
| GB201703224D0 (en) | 2017-04-12 |
| US10647999B2 (en) | 2020-05-12 |
| AU2017225350B2 (en) | 2023-07-20 |
| SG11201806782QA (en) | 2018-09-27 |
| US20190071692A1 (en) | 2019-03-07 |
| EP3686282B1 (en) | 2024-12-04 |
| GB2578859B (en) | 2020-10-28 |
| GB201603577D0 (en) | 2016-04-13 |
| EP3423583B1 (en) | 2023-05-24 |
| GB2553170A (en) | 2018-02-28 |
| GB2578859A (en) | 2020-05-27 |
| GB202002193D0 (en) | 2020-04-01 |
| EP3423583A1 (en) | 2019-01-09 |
| EP3686282A1 (en) | 2020-07-29 |
| JP2019506882A (ja) | 2019-03-14 |
| CN109072251A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102755545B1 (ko) | 프로모터 | |
| JP4550115B2 (ja) | ＣｐＧ含量を変化させることにより遺伝子発現を調整する方法 | |
| CA2304207A1 (en) | Rna export element and methods of use | |
| US9234197B2 (en) | Genetic element that enhances protein translation | |
| CN109929839A (zh) | 拆分型单碱基基因编辑系统及其应用 | |
| JP2022528252A (ja) | 環状ｒｎａを使用したタンパク質翻訳およびその応用 | |
| JP2015501642A (ja) | 発現カセット | |
| US20250136961A1 (en) | Isolated nuclease and use thereof | |
| HK40034561A (en) | Promoter | |
| EP3341484B1 (en) | Mammalian expression system | |
| Ghassemi et al. | Translational efficiency of BVDV IRES and EMCV IRES for T7 RNA polymerase driven cytoplasmic expression in mammalian cell lines | |
| HK40034561B (en) | Promoter | |
| WO2014092094A1 (ja) | 発現カセット | |
| WO2005090562A1 (ja) | 軽度の低温により遺伝子の発現を促進させる配列 | |
| HK40001212A (en) | Promoter | |
| HK40001212B (en) | Promoter | |
| KR102749407B1 (ko) | 하이브리드 프로모터 | |
| CN113584085B (zh) | 一种针对悬浮细胞的慢病毒载体及其应用 | |
| CN114807145B (zh) | 一种提高非帽子依赖翻译效率的前导序列及其应用 | |
| WO2025064834A1 (en) | Isolated betacoronavirus ires sequences | |
| KR20250168514A (ko) | 비-ltr 레트로트랜스포존 시스템 및 이의 용도 | |
| CN116218880A (zh) | 一种提高病毒滴度的重组载体及其制备方法和应用 | |
| KR20250166293A (ko) | 단리된 트랜스포사제 및 이의 용도 | |
| JP2017000015A (ja) | 目的遺伝子の発現誘導可能なウイルスベクター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180829 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211028 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240131 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241204 |
|
| PG1601 | Publication of registration |